Oligometastasis, Pancreatic Cancer Metastatic to Liver
Conditions
Keywords
Pancreatic Cancer Metastatic to Liver, Oligometastasis, Microwave Ablation, overall survival
Brief summary
This study is a prospective, single center, single arm, phase II clinical study in patients with liver metastasis after radical resection of pancreatic cancer. The purpose of this study is to evaluate the clinical value of microwave ablation combined with chemotherapy for liver metastasis after radical resection of pancreatic cancer about overall survival, and to determine the feasibility and safety of the scheme.
Detailed description
Microwave ablation, as one of the important treatment methods of liver metastases, has the advantages of radical effect, small trauma and rapid recovery.Microwave ablation combined with chemotherapy aims to improve the quality of life and prolong the survival time.The purpose of this study is to evaluate the clinical value of microwave ablation combined with chemotherapy for liver metastasis after radical resection of pancreatic cancer about overall survival, and to determine the feasibility and safety of the scheme.
Interventions
COMBINATION_PRODUCTMicrowave Ablation combination with chemotherapy
Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18 to 75years old, male or female; * ECOG PS: 0-2 points; * Patients with pancreatic ductal adenocarcinoma diagnosed by histology or cytology; * Expected survival time\> 3 months; * The functions of important organs meet the following requirements; * The maximum diameter of single lesion ≤ 5cm or the number of multiple lesions ≤ 5 and the maximum diameter ≤ 3cm; * Measurable lesions that meet RECIST criteria. 1. Platelet ≥75×109/L, hemoglobin ≥85g/L，white blood cell ≥ 3.0 × 109 / L; 2. Total bilirubin ≤ 1.5 times upper limit of normal value (ULN) ; ALT and AST ≤ 5 times ULN ; 3. Albumin ≥ 28g / L; 4. Creatinine ≤ 1.5 times ULN, or creatinine clearance rate ≥ 50ml / min; * Women of childbearing age must undergo a negative pregnancy test (βHCG) before starting treatment. Women and men of childbearing age (sexual relationships with women of childbearing age) must agree to use them effectively during treatment and 3 months after the last dose of treatment Contraceptive measures; * Signature of patient information and informed consent. * Patients who did not participate in other clinical trials within 4 weeks before screening; those who failed in other trials but met the requirements of this trial could be enrolled.
Exclusion criteria
* Patients with distant metastasis include but not limited to lung metastasis, bone metastasis and brain metastasis; * Other serious diseases or conditions, including congestive heart failure (NYHA grade III or IV), unstable angina, myocardial infarction and cerebral infarction in the past 6 months, severe arrhythmia, prolonged QT interval, active HIV infection or HIV disease, mental disorders, drug abuse, etc; * Women who are pregnant or nursing, or have fertility but refuse to take contraceptive measures; * During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred; * In addition to cervical carcinoma in situ, basal cell carcinoma and superficial bladder tumor (TA, tis & T1). Any cancer cured for more than 3 years before enrollment was allowed to be enrolled; * Patients who cannot follow the trial protocol or cannot cooperate with follow-up;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | 24months | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-month PFS | 6months | From date of starting treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months. |
| ORR | From the first drug administration up to two years | Overall Response Rate |
| DCR | From the first drug administration up to two years | Disease Control Rate |
| Complete ablation rate | From the first drug administration up to two years | The complete ablation rate was evaluated by abdominal enhanced MRI or CT at 4 weeks after operation |
Countries
China
Contacts
Primary ContactYongqiang Hua, Deputy chief physician
Outcome results
None listed